Bladder cancer (BlCa) is the second most common genitourinary cancer, affecting both men and women. Most (70%) cases present at the superficial stage; 20% of these recur with muscle-invasive disease. Major genetic alterations associated with BlCa include: loss/gain in expression or mutations in Retinoblastoma (RB) gene, human epidermal growth factor receptors (HERs), H-ras, p53 and FGFR3. Only p53 mutations are well correlated with invasive BlCa; other changes show variable correlations with disease status. To understand the progression of BlCa, a model of nine human BlCa cell sublines derived from a single parent but differing in in vivo characteristics, has been developed previously. These cells represent a heterogenous population from a ...
Bladder cancer is one of the most frequent malignancies in developed countries and it is also charac...
Urinary bladder cancer is the 11th most common cancer when considering both sexes together and the 7...
textabstractBackground: Fifty percent of patients with muscle-invasive bladder cancer (MI-BC) die fr...
A human bladder cancer model of nine cell sublines derived from the BL17/2 cell line was used to eva...
Bladder cancer (BC) comes in two flavors: as non-muscle invasive (NMI) and as muscle invasive (MI) d...
Transitional cell carcinoma of the bladder is a common tumor. While most patients presenting superfi...
Bladder cancer is a global health issue with sex differences in incidence and prognosis. Bladder can...
SummaryMuscle-invasive bladder cancers (MIBCs) are biologically heterogeneous and have widely variab...
Carcinoma in situ (CIS) of the bladder has recently been proposed to be a heterogeneous group of dis...
An estimated 9,000 Canadians are diagnosed with bladder cancer each year making it the 5th most comm...
Molecular changes occurring during invasion and clinical progression of cancer are difficult to stud...
Bladder cancer is a highly prevalent disease associated with substantial morbidity, mortality and co...
Problem Statement: Transitional Cell Carcinoma (TCC) of the bladder is a significant health problem ...
Muscle-invasive bladder cancers (MIBCs) are biologically heterogeneous and have widely variable clin...
Bladder cancer is the 4th commonest malignancy in the United Kingdom and worldwide there are nearly ...
Bladder cancer is one of the most frequent malignancies in developed countries and it is also charac...
Urinary bladder cancer is the 11th most common cancer when considering both sexes together and the 7...
textabstractBackground: Fifty percent of patients with muscle-invasive bladder cancer (MI-BC) die fr...
A human bladder cancer model of nine cell sublines derived from the BL17/2 cell line was used to eva...
Bladder cancer (BC) comes in two flavors: as non-muscle invasive (NMI) and as muscle invasive (MI) d...
Transitional cell carcinoma of the bladder is a common tumor. While most patients presenting superfi...
Bladder cancer is a global health issue with sex differences in incidence and prognosis. Bladder can...
SummaryMuscle-invasive bladder cancers (MIBCs) are biologically heterogeneous and have widely variab...
Carcinoma in situ (CIS) of the bladder has recently been proposed to be a heterogeneous group of dis...
An estimated 9,000 Canadians are diagnosed with bladder cancer each year making it the 5th most comm...
Molecular changes occurring during invasion and clinical progression of cancer are difficult to stud...
Bladder cancer is a highly prevalent disease associated with substantial morbidity, mortality and co...
Problem Statement: Transitional Cell Carcinoma (TCC) of the bladder is a significant health problem ...
Muscle-invasive bladder cancers (MIBCs) are biologically heterogeneous and have widely variable clin...
Bladder cancer is the 4th commonest malignancy in the United Kingdom and worldwide there are nearly ...
Bladder cancer is one of the most frequent malignancies in developed countries and it is also charac...
Urinary bladder cancer is the 11th most common cancer when considering both sexes together and the 7...
textabstractBackground: Fifty percent of patients with muscle-invasive bladder cancer (MI-BC) die fr...